TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE
B Andemariama, A Inatib, R Colombattic, C Minnitid, C Browne, M Hottmanne, S Graye, C Hoppee, F Montealegre-Golchere, P Yuee
a New England Sickle Cell Institute, University of Connecticut Health, Farmington, United States
b Lebanese American University, Byblos and Beirut, Nini Hospital, Beirut, Lebanon
c Clinic of Pediatric Hematology Oncology, Department of Woman's and Child's Health, Azienda Ospedale – Università di Padova, Padua, Italy
d Albert Einstein College of Medicine, New York, United States
e Global Blood Therapeutics
Lido
1559
Vezesque se leu este artigo
687
Total PDF
872
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 7 | 56 | 32 | 88 |
| 2025 6 | 40 | 20 | 60 |
| 2025 5 | 53 | 12 | 65 |
| 2025 4 | 38 | 14 | 52 |
| 2025 3 | 54 | 15 | 69 |
| 2025 2 | 37 | 17 | 54 |
| 2025 1 | 38 | 26 | 64 |
| 2024 12 | 32 | 21 | 53 |
| 2024 11 | 33 | 19 | 52 |
| 2024 10 | 34 | 23 | 57 |
| 2024 9 | 33 | 19 | 52 |
| 2024 8 | 39 | 24 | 63 |
| 2024 7 | 34 | 20 | 54 |
| 2024 6 | 43 | 34 | 77 |
| 2024 5 | 41 | 26 | 67 |
| 2024 4 | 23 | 19 | 42 |
| 2024 3 | 23 | 22 | 45 |
| 2024 2 | 17 | 29 | 46 |
| 2024 1 | 9 | 13 | 22 |
| 2023 12 | 11 | 16 | 27 |
| 2023 11 | 20 | 29 | 49 |
| 2023 10 | 17 | 35 | 52 |
| 2023 9 | 27 | 26 | 53 |
| 2023 8 | 20 | 24 | 44 |
| 2023 7 | 14 | 11 | 25 |
| 2023 6 | 16 | 23 | 39 |
| 2023 5 | 15 | 16 | 31 |
| 2023 4 | 18 | 24 | 42 |
| 2023 3 | 3 | 8 | 11 |
| 2023 2 | 7 | 14 | 21 |
| 2023 1 | 6 | 7 | 13 |
| 2022 12 | 9 | 23 | 32 |
| 2022 11 | 8 | 19 | 27 |
| 2022 10 | 4 | 7 | 11 |
Mostrar tudo
